# An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy

> **NCT01674595** · PHASE2,PHASE3 · COMPLETED · sponsor: **ALK-Abelló A/S** · enrollment: 93 (actual)

## Conditions studied

- Allergic Rhinitis Due to Olea Europaea Pollen

## Interventions

- **BIOLOGICAL:** AVANZ olea

## Key facts

- **NCT ID:** NCT01674595
- **Lead sponsor:** ALK-Abelló A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2013-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01674595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01674595, "An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01674595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*